Evidence map›Paper›PMID 38093611›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19.

Karol Biernacki, Olga Ciupak, Mateusz Daśko, Janusz Rachon, Damian Flis, Justyna Budka, Iwona Inkielewicz-Stępniak, Anna Czaja, Janusz Rak, Sebastian Demkowicz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Karol BiernackiDepartment of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
Olga CiupakDepartment of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
Mateusz DaśkoDepartment of Inorganic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
Janusz RachonDepartment of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
Damian FlisDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, Gdańsk, Poland.
Justyna BudkaDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, Gdańsk, Poland.
Iwona Inkielewicz-StępniakDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, Gdańsk, Poland.
Anna CzajaDepartment of Physical Chemistry, University of Gdańsk, Gdańsk, Poland.
Janusz RakDepartment of Physical Chemistry, University of Gdańsk, Gdańsk, Poland.
Sebastian DemkowiczDepartment of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
Gdańsk University of Technology · PLGdańsk Medical University · PLUniversity of Gdańsk · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present work, we report a new series of potent SARS-CoV-2 Main Protease (Mpro) inhibitors based on maleimide derivatives. The inhibitory activities were tested in an enzymatic assay using recombinant Mpro (3CL Protease from coronavirus SARS-CoV-2). Within the set of new Mpro inhibitors,

Indexed as

COVID-19Antiviral AgentsCoronavirus 3C ProteasesHEK293 CellsHumansLactamsLeucineMaleimidesMolecular Docking SimulationNitrilesProtease InhibitorsSARS-CoV-23C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesLactamsLeucinemaleimideMaleimidesNitrilesProtease InhibitorsCoronavirus SARS-CoV-2COVID-19maleimide derivativesSARS-CoV-2 main protease mpro inhibitors

Identifiers

PMID38093611
PMCPMC10732195
OpenAlexW4389767135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.